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Background: Patients with bipolar disorder spend approximately half of their lives symptomatic and 
the majority of that time suffering from symptoms of depression, which complicates the accurate 
diagnosis of bipolar disorder.
Methods: Challenges in the differential diagnosis of bipolar disorder and major depressive disorder are 
reviewed, and the clinical utility of several screening instruments is evaluated.
Results: The estimated lifetime prevalence of major depressive disorder (i.e., unipolar depression) is 
over 3 and one-half times that of bipolar spectrum disorders. The clinical presentation of a major 
depressive episode in a bipolar disorder patient does not differ substantially from that of a patient with 
major depressive disorder (unipolar depression). Therefore, it is not surprising that without proper 
screening and comprehensive evaluation many patients with bipolar disorder may be misdiagnosed 
with major depressive disorder (unipolar depression). In general, antidepressants have demonstrated 
little or no efficacy for depressive episodes associated with bipolar disorder, and treatment guidelines 
recommend using antidepressants only as an adjunct to mood stabilizers for patients with bipolar 
disorder. Thus, correct identification of bipolar disorder among patients who present with depression 
is critical for providing appropriate treatment and improving patient outcomes.
Limitations: Clinical characteristics indicative of bipolar disorder versus major depressive disorder 
identified in this review are based on group differences and may not apply to each individual patient.
Conclusion: The overview of demographic and clinical characteristics provided by this review may 
help medical professionals distinguish between major depressive disorder and bipolar disorder. 
Several validated, easily administered screening instruments are available and can greatly improve the 
recognition of bipolar disorder in patients with depression.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
Although mania and hypomania are the signature and most 
recognizable characteristics of bipolar disorder, depression is its 
most frequent clinical presentation. This is dramatically demon-
strated in a long-term follow-up of 146 patients with bipolar I 
disorder, which found that nearly half of the time over 13 years 
patients were symptomatic in some fashion, overwhelmingly 
with depressive symptoms (Judd et al., 2002). Thus, nearly 40% 
of the time over 13 years, individuals with bipolar disorder were 
depressed. In contrast, patients were manic or hypomanic less 
than 10% of the time and without symptoms about half the time 
(Judd et al., 2002). The predominance of depressive compared with 
mood elevation symptoms was even greater when considering 
patients with bipolar II disorder (Judd et al., 2003).
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Bipolar patients are much more likely to present to clinicians, 
especially in outpatient settings, when they are depressed 
(Hirschfeld et al., 2005). However, unipolar depression is more 
prevalent than bipolar disorder: the lifetime prevalence of 
unipolar major depressive disorder is 16.2%, whereas the lifetime 
prevalence of bipolar spectrum disorders is 4.5% (Table 1) (Kessler 
et al., 2003; Merikangas et al., 2007). The clinical presentation of 
a patient with bipolar disorder when depressed may not differ 
from that of a non-bipolar depressed patient. In light of the higher 
prevalence of unipolar depression compared with bipolar disorder 
and the similarities in clinical presentation of a depressive episode 
in both unipolar and bipolar depression, without appropriate 
screening, bipolar patients may be misdiagnosed.
Several studies have addressed the prevalence of bipolar 
disorder in patients with depressive symptoms. In a general 
population sample of 85,358 US adults aged 18 or older, nearly 
4% screened positive for bipolar disorder using the Mood Disorder 
Questionnaire (MDQ) (Hirschfeld et al., 2003a). Most of those 
who screened positive for bipolar disorder had never received a 
diagnosis of bipolar disorder, and nearly a third reported having 
been diagnosed with unipolar depression (Hirschfeld et al., 
2003a). In a primary care clinic, 21% of patients being treated 
for depression screened positive for bipolar disorder, and nearly 
two-thirds of those patients reported they had never received 
a diagnosis of bipolar disorder before (Hirschfeld et al., 2005). 
The figures are somewhat higher for psychiatric samples, where 
estimates suggest that up to more than 49% of depressed patients 
may have bipolar disorder (Benazzi, 1997). This finding strongly 
confirms that there are many people suffering from bipolar 
disorder in depressed samples, most of whom are not recognized 
as being bipolar, suggesting that the true prevalence, as discussed 
above, may not be accurate.
2. Consequences of misdiagnosis
There are significant potential consequences of misdiagnosing 
a bipolar disorder patient experiencing a depressive episode as 
having unipolar depression and treating the patient as though he 
or she is suffering from a unipolar depression. In general, standard 
antidepressant therapy has not been shown to be effective in the 
treatment of depression episodes in patients with bipolar disorder, 
and treatment guidelines recommend using antidepressants only 
as adjunct therapy to mood stabilizers for bipolar depression 
(Goodwin, 2009; Yatham et al., 2013).
Several antidepressants, including paroxetine, imipramine, 
sertraline, fluoxetine and bupropion, have been studied as 
treatments for depression in bipolar disorder patients adjunctive 
with mood stabilizers. In general, with the important exception 
of fluoxetine in combination with olanzapine (Tohen et al., 2003), 
adjunctive use of these antidepressants has shown modest efficacy 
at best (Nemeroff et al., 2001; Post et al., 2001; Sachs et al., 2007). 
In the Systematic Treatment Enhancement Program for Bipolar 
Disorder trial, neither adjunctive (added to mood stabilizer or 
antipsychotic) paroxetine nor adjunctive bupropion was found to 
be more effective than adjunctive placebo in yielding sustained 
or transient recovery (Sachs et al., 2007). In a placebo-controlled 
study that evaluated monotherapy with paroxetine or quetiapine 
for the treatment of bipolar depression, paroxetine 20 mg/day 
was not found to be more efficacious than placebo, whereas 
quetiapine 300 mg/day and 600 mg/day was more efficacious 
than placebo (McElroy et al., 2010). Although antidepressants 
are widely used in the treatment of such patients (Baldessarini 
et al., 2008; Baldessarini et al., 2007; Ghaemi et al., 1999), these 
research studies do not support the efficacy of antidepressants 
alone or as adjunctive to mood stabilizers in the treatment of 
bipolar depression.
Whether the prescription of antidepressants for bipolar patients 
causes harm is a subject of considerable debate. Earlier studies 
indicated that antidepressants could cause an acceleration of 
mood cycles and an overall destabilization of patients with bipolar 
disorder in addition to precipitating a manic or hypomanic episode 
(Altshuler et al., 1995; Boerlin et al., 1998; Peet, 1994; Wehr et 
al., 1988). These studies involved the earlier antidepressants, 
particularly tricyclic antidepressants. More recent studies of the 
selective serotonin reuptake inhibitors (SSRIs) do not, in general, 
support destabilization or switch into mania (Sidor and MacQueen, 
2011), at least with shorter-term treatment.
The overall conclusion from this research and the use of 
SSRI antidepressants in patients with bipolar disorder is that 
they in general are not particularly effective in terms of treating 
depression, but they may not be as dangerous as originally 
believed.
3. Identifying bipolar patients in depressed samples
The key clinical question at this point is how to identify 
patients with bipolar disorder among the patients presenting with 
symptoms of depression, to ensure that these patients receive 
proper treatment. There are several demographic and clinical 
characteristics that are more commonly observed in bipolar 
disorder compared with unipolar depression (Table 2) (Goodwin 
and Jamison, 2007).
Patients with bipolar disorder are much more likely to have a 
family history of bipolar disorder (Goodwin and Jamison, 2007). 
With regard to clinical course, patients with bipolar disorder 
typically have an earlier age of onset than those with unipolar 
depression. People with bipolar disorder have a mean age of 
onset of 22 years, whereas those with unipolar depression have 
an average age of onset of 26 years (Goodwin and Jamison, 2007; 
Zisook et al., 2007). Symptoms of bipolar disorder may occur 
even earlier in many patients: in one survey, nearly two-thirds 
of respondents said that they had significant symptoms of the 
disorder prior to age 19 (Hirschfeld et al., 2003b).
Those with bipolar disorder also are much more likely to have 
had a greater number of prior affective episodes and perhaps 
psychiatric hospitalizations than unipolar depressed patients 
(Goldberg and Harrow, 2004; Goodwin and Jamison, 2007). They 
are more likely to have a history of treatment-resistant depression. 
They may have had difficulties with antidepressant treatment, 
such as becoming more depressed or irritable or experiencing 
mood elevation symptoms during antidepressant treatment. 
In fact, they may have even shifted into mania or hypomania 
on antidepressants. Patients with bipolar disorder may display 
marked seasonality, most often experiencing depression during 
winter months. They may also have had more prior suicide 
attempts than patients with unipolar depression (Goodwin and 
Jamison, 2007; Rihmer and Kiss, 2002).
With regard to clinical presentation, individuals with bipolar 
disorder are more likely to display mood reactivity rather than 
simply sad mood (Goodwin and Jamison, 2007). There may be 
Table 1
Lifetime prevalence of bipolar disorders and major depressive disorder.
Disorder  Prevalence (%)
Bipolar disorder I 1.0
Bipolar disorder II 1.1
Subthreshold bipolar disorder 2.4
All bipolar disorders 4.5
 
Major depressive disorder 16.2
Data from Kessler, R.C. et al., 2003, JAMA 289 (23), 3095-3105; and 
Merikangas, K.R., et al., 2007, Arch. Gen. Psychiatry 64 (5), 543-552.
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symptoms associated with mania or hypomania during depressive 
episodes in this population, particularly increased motor activity, 
rapid or pressured speech, and grandiose or other delusions. 
Patients with bipolar disorder, when depressed, are more likely 
to experience “inverse” neuro-vegetative symp toms, particularly 
hypersomnia, weight gain, and increased appetite. They also are 
more likely to be psychotic (Goodwin and Jamison, 2007) and have 
cognitive impairment (Borkowska and Rybakowski, 2001; Wolfe 
et al., 1987). Conversely, patients with unipolar depression are 
more likely to experience typical depressive symptoms including 
insomnia, sad mood, and somatic depressive and anxiety 
symptoms (Goodwin and Jamison, 2007).
4. Screening for bipolar disorder and measures of depression
Recognition of bipolar disorder in patients with depression 
may be improved by using screening instruments (Table 3). The 
most widely used screening instrument for bipolar disorder is the 
MDQ, a validated self-rated questionnaire that screens patients 
for bipolar disorder; however, it is not a diagnostic instrument 
(Hirschfeld et al., 2000).
The MDQ consists of 15 questions and takes approximately 
5 minutes to complete (Hirschfeld et al., 2000). The first 
13 questions are designed to identify manic or hypomanic 
symptoms the patient may have experienced in the past. The last 
2 questions assess symptom clusters and functional impairment. 
Patients who answer yes to at least 7 of the first 13 questions and 
the symptom cluster question, as well as “moderate problem” or 
“serious problem” on the functional impairment question, are 
considered to be a positive screen for bipolar disorder. The MDQ 
had a sensitivity of 0.73 and a specificity of 0.90 in a validation 
study of 198 psychiatric outpatients, indicating that the MDQ can 
correctly identify almost three-quarters of patients with bipolar 
disorder and will screen out bipolar disorder in 9 of 10 patients 
without the condition (Hirschfeld et al., 2000). It has been widely 
used throughout the world, having been translated into 19 
languages and cited in more than 600 publications.
The Hypomania/Mania Symptom Checklist (HCL-32), another 
validated self-report screening tool for bipolar disorder (Angst 
et al., 2005), has 2 introductory questions, the first on the 
subject’s current emotional state, and the second on the subject’s 
usual level of activity, energy, and mood. Following this are 32 
questions, most of which address specific symptoms of mania 
and hypomania. Other HCL-32 questions are more general, 
including questions on whether patients get into more quarrels, 
drink more coffee or alcohol, or smoke more cigarettes when 
they are in a manic state. A score is calculated by summing the 
number of positive responses to the 32 questions in the third 
section. A score of 14 or greater is considered positive for bipolar 
disorder. The HCL-32 has a sensitivity of 0.8 and a specificity of 
0.51 (Angst et al., 2005).
Both the MDQ and the HCL-32 are validated, useful screening 
instruments for bipolar disorder. The MDQ was introduced 
earlier and has been more widely used than the HCL-32, and may 
be preferred because it is shorter and can be completed more 
quickly.
Another widely used self-report instrument that can be 
completed very quickly is the Patient Health Questionnaire 
(PHQ-9). The PHQ-9 is a multi-purpose instrument used for 
screening, diagnosing, monitoring, and measuring the severity 
of depression (Spitzer et al., 1999). It has 9 questions, some of 
which incorporate Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) diagnostic criteria, along with 
others describing other symptoms of major depressive disorder 
(such as decreased interest or pleasure, loss of appetite, and poor 
energy). Each question is graded from zero to 3, depending on the 
frequency of a symptom. A total score is calculated by adding the 
responses to each of the 9 questions, indicating a categorization of 
no depression to severe depression (Spitzer et al., 1999).
The most important differences between the PHQ-9 and 
both the MDQ and HCL-32 are the symptoms assessed and 
when these symptoms occurred. The MDQ and HCL-32 focus 
on assessing lifelong symptoms of mania and hypomania, while 
the PHQ-9 assesses current depressive symptoms (Angst et al., 
2005; Hirschfeld et al., 2000; Spitzer et al., 1999). The PHQ-9 has 
a sensitivity of 88% and a specificity of 88% for major depressive 
episodes (Kroenke and Spitzer, 2002; Kroenke et al., 2001), but 
does not address the challenge of distinguishing bipolar disorder 
from major depressive disorder.
There are several other instruments available to assess the 
occurrence and severity of depressive symptoms. The Beck 
Depression Inventory (BDI), developed by Aaron Beck, was 
originally published in 1961 (Beck et al., 1961) and revised in 
1996 to align with DSM-IV diagnostic criteria for major depressive 
disorder (Beck et al., 1996a). The main version consists of 21 
questions reflecting the symptoms of depression, with responses 
ranging from zero to 3 on degree of severity. Examples of questions 
include: “I am sad all the time,” “I am disappointed in myself,” 
and “I am too tired or fatigued to do most of the things I used to 
do” (Beck et al., 1996b). These responses are summed to create a 
total score, which then will translate into diagnosis of minimal to 
severe depression (Beck et al., 1961). The original BDI and other 
variations of it have also been used very widely in clinical and 
research settings.
The Inventory of Depressive Symptomology (IDS-SR) was 
developed by John Rush and colleagues to provide a more 
sensitive measure for assessing depression in outpatients than 
the Hamilton Depression Rating Scale (HAM-D) (Rush et al., 
1996). Originally 28 items (Rush et al., 1986), the current version 
is a 30-item self-report scale that includes 2 additional questions 
assessing the atypical features included in DSM-IV and was 
validated in 1996 (Rush et al., 1996). Details on a 16-item Quick 
Inventory of Depressive Symptomology (QIDS), also developed 
by Rush and colleagues, were first published in 2003 (Rush et 
al., 2003). Similar to the other self-report inventories, the IDS 
and the QIDS include items that assess symptoms of depression 
such as waking up too early, energy level, and thoughts of death 
or suicide (Rush et al., 1996; Rush et al., 2003). The IDS and the 
QIDS were developed to provide equivalent weightings for each 
symptom item (other scales have variable weights), clear anchors 
for symptom frequency and severity, inclusion of all symptoms 
in the DSM-IV major depressive episode criteria, and to provide 
parallel clinician-rated and patient-rated scales (Rush et al., 1996; 
Rush et al., 2003).
The PHQ-9 is probably the best choice for general patient 
screening for depression because of its brevity and widespread 
use. The BDI is more sensitive to change in clinical state and, 
Table 2
Possible indicators of bipolar disorder in depressed patients.
Family history of bipolar disorder
Earlier onset of illness (early 20’s)
Seasonality
Numerous past episodes
History of psychiatric hospitalization
Mixed states
Mood reactivity
History of treatment-resistant depression
Switching on antidepressants
History of suicide attempt
Data from Goodwin, F.K., Jamison, K.R., 2007. Manic-Depressive Illness: 
Bipolar Disorders and Recurrent Depression. 2nd ed. Oxford University Press, 
New York, NY.
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therefore, may be more useful for monitoring these clinical 
states in depressed patients. Although the IDS is much less well-
known than the BDI, it is more balanced in terms of symptom 
contributions and may be more sensitive than the BDI to changes 
in clinical status.
There are 2 clinician-administered rating scales for depression 
that are used in both clinical and research settings: the HAM-D and 
the Montgomery-Åsberg Depression Rating Scale (MADRS). The 
HAM-D was developed by Max Hamilton in England more than 
50 years ago (Hamilton, 1960). It requires a clinically experienced 
rater to provide numerical ratings on 21 depressive symptoms. 
Examples include depressed mood, feelings of guilt, and agitation 
(Hamilton, 1960). There are several different versions of the 
HAM-D with different numbers of items. It is the most widely 
used assessment instrument for clinician-rated depression in the 
world and has been used in many clinical trials.
The MADRS was developed by Montgomery and Åsberg nearly 
40 years ago to be more sensitive to changes in depressed clinical 
state than the HAM-D, particularly for use in trials to test the 
efficacy of antidepressant medication (Montgomery and Åsberg, 
1979). It consists of 10 clinician-administered items, each of which 
may be rated from zero to 6. Items include apparent sadness, 
reported sadness, lassitude, and suicidal thoughts (Montgomery 
and Åsberg, 1979). The MADRS also has been used very widely in 
research studies.
It is important to keep in mind that the PHQ-9, BDI, HAM-D, 
and MADRS do not address the bipolar versus unipolar diagnostic 
challenge.
5. Conclusion
Bipolar disorder is highly prevalent in samples of depressed 
patients and can easily be missed, which can have negative 
consequences. Careful clinical assessment, including screening 
for bipolar disorder by investigating whether there is a history of 
manic or hypomanic episodes (by using a scale like the MDQ), can 
help substantially with correctly identifying patients with bipolar 
disorder. Although there are multiple validated instruments to 
diagnose major depressive episodes, most do not address the 
bipolar versus unipolar diagnostic challenge.
Conflict of interest
For the period 10/1/2010 through 9/31/2013, Dr. Hirschfeld has received 
royalties from Jones & Bartlett. He also has been a consultant for Grey Healthcare 
Group, bioStrategies Group, Merck Manual Editorial Board, and Equinox Group. 
Additionally, he has received honoraria from Physicians Postgraduate Press, Inc, 
Health and Wellness Partners, Merck Manual Editorial Board, CME Outfitters, 
Letters & Sciences, Nevada Psychiatric Association, and CMEology.
Funding/support
Funding for editorial support was provided by Teva Pharmaceuticals, North 
Wales, PA. Publication of this manuscript was supported by an independent 
medical education grant from Sunovion Pharmaceuticals, Marlborough, MA.
Contributor’s statement
Robert M.A. Hirschfeld, MD, wrote the initial draft of the manuscript, has 
approved every edit, and has approved the final manuscript. Editorial assistance 
was provided by Synchrony Medical LLC, including editorial edits, comments, 
and drafting an abstract. Dr Hirschfeld has contributed to and approved the final 
manuscript. Keitha S. Moseley-Dendy, MA, has also provided editorial assistance.
Table 3
An overview of screening tools for bipolar disorder and depression.
  Type of Scale Number of Questions Duration Scoring Algorithm
Bipolar Scales
 Mood Disorder Questionnaire  Self-report 15 <10 minutes Yes >7 of the first 13 questions and the symptom 
 (Hirschfeld et al., 2000)     cluster question, as well as “moderate problem” or 
     “serious problem” on the functional impairment  
     question, = positive screen for bipolar disorder
 Hypomania/Mania Symptom Self-report 32 (plus 2 unscored <15 minutes Total score ≥14 = potentially bipolar
 Checklist (Angst et al., 2005)   introductory items)
Depression Scales
 Patient Health Questionnaire  Self-report 9 <5 minutes Total score 5–9 = minimal symptoms 
 (Spitzer et al., 1999)    Total score 10–14 = mild depression
     Total score 15–19 = moderately severe depression
     Total score >20 = severe depression
 Beck Depression Inventory-II Self-report 21 <10 minutes Total score 0–9 = minimal depression
 (Beck et al., 1996b)    Total score 10–18 = mild depression
     Total score 19–29 = moderate depression
     Total score 30–63 = severe depression
 Inventory of Depressive Self-report 30 (IDS) <15 minutes (IDS) Total scores 
 Symptomology (IDS) and  or clinician-rated 16 (QIDS) <7 minutes (QIDS) 0–13 (IDS)/0–5 (QIDS) = none 
 Quick Inventory of Depressive    14–25 (IDS)/6–10 (QIDS) = mild
 Symptomology (QIDS)     26–38 (IDS)/11–15 (QIDS) = moderate
 (Rush et al., 1996;     39–48 (IDS)/16–20 (QIDS) = severe
 Rush et al., 2003)    49–84 (IDS)/21–27 (QIDS) = very severe
 Hamilton Depression Clinician-rated 21 (score 1st 17 only) <20 minutes Total score 0–7 = normal
 Rating Scale    Total score 8–13 = mild depression
 (Hamilton, 1960)    Total score 14–18 = moderate depression
     Total score 19–22 = severe depression
     Total score ≥23 = very severe depression
 Montgomery-Åsberg Clinician-rated 10 <15 minutes Total score 0–6 = absence of symptoms 
 Depression Rating Scale     Total score 7–19 = mild depression 
 (Montgomery and Åsberg,     Total score 20–34 = moderate depression
 1979; Snaith et al., 1986)    Total score 35–60 = severe depression
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